4D pharma

Leader in Live Biotherapeutics

NASDAQ: $LBPS
AIM: $DDDD

[4D pharma @4dpharmaplc]

@MicrobiomeFirst Trial in #asthma 'folk' is up and running, see https://t.co/HfFDpfPi0s for more info including eligibility and participating sites

[4D pharma @4dpharmaplc]

@MicrobiomeFirst It's going pretty well so far @MicrobiomeFirst ! World first data recently presented at #ATS2022
https://t.co/eUqMlyRTvI

[4D pharma @4dpharmaplc]

This month's @ScienceMagazine Special Issue: The Systemic Microbiome.
"Understanding the ecology and the mechanisms of cross-talk between host and microbiota will one day contribute to preventing and treating a spectrum of human diseases."
https://t.co/vouS3BufWm

[4D pharma @4dpharmaplc]

We are pleased to be presenting our Phase II trial of #LiveBiotherapeutic MRx0518 with Bavencio as a first-line maintenance therapy for #UrothelialCarcinoma at #ASCO22

Session: Genitourinary Cancer - Kidney and Bladder. Saturday, June 4, 2022 at 13:15 CDT

$LBPS #DDDD

[4D pharma @4dpharmaplc]

On #clinicaltrialsday , @ParkinsonsUK have written about one of 4D pharma's lunch and learn sessions, highlighting the importance of engaging patients in clinical research.

https://t.co/6210qOWyr9

#microbiome #DDDD $LBPS

[4D pharma @4dpharmaplc]

Results from Part A of @4dpharmaplc's trial of #LiveBiotherapeutic MRx-4DP0004 for the treatment of #asthma have been selected as a late-breaking abstract at #ATS2022 @atscommunity
These results support the potential of MRx-4DP0004 as a novel oral immunomodulator asthma therapy

[4D pharma @4dpharmaplc]

CEO Duncan Peyton stopped by the #BusinessOfBiotech podcast with @mattpillar @BioProcessOL @Cytiva to discuss how @4dpharmaplc is defining a new class of drug with our #LiveBiotherapeutics and the challenges overcome along the way

https://t.co/efMQXosAaz

#microbiome #DDDD $LBPS

[4D pharma @4dpharmaplc]

On #WorldParkinsonsDay we are proud to be working with @ParkinsonsUK to raise awareness and support research into new therapies for #Parkinsons

Brave souls from @4dpharmaplc will be attempting the infamous @ToughMudder and you can show your support at:
https://t.co/3EWEfhZJ6Z

[4D pharma @4dpharmaplc]

Today Dr Imke Mulder, EVP Research, will present at the Microbiome & Probiotics R&D and Business Collaboration Forum #MicrobiomeForum on developing #LiveBiotherapeutics for neurodegenerative disease as we look ahead to initiating a first-in-human trial in #Parkinsons in 2022

[4D pharma @4dpharmaplc]

Join us in 30 minutes us for a conference call and webcast to discuss this morning's results for MRx0518 and Keytruda in renal cell carcinoma (RCC) and current treatment landscape, alongside KOLs @PGrivasMDPhD and @DrScottTagawa
Register via https://t.co/PSXSgvQduC
$LBPS #DDDD

[4D pharma @4dpharmaplc]

Today we announced the #renalcellcarcinoma group in Part B of our Phase I/II study of #LiveBiotherapeutic MRx0518 with #Keytruda has met the primary efficacy endpoint ahead of full enrollment.

Read the full release at https://t.co/1t91lie87w

$LBPS #DDDD

[4D pharma @4dpharmaplc]

Today we announced the #renalcellcarcinoma group in Part B of our Phase I/II study of #LiveBiotherapeutic MRx0518 with #Keytruda has met the primary efficacy endpoint ahead of full enrollment.

Read the full release at https://t.co/1t91lie87w

$LBPS #DDDD

[4D pharma @4dpharmaplc]

4D Gets Green Light to Test First Live Biotherapeutic for Parkinson's

"With IND approval, the therapeutics have become the first LBPs for Parkinson’s disease cleared by the FDA"

@biospace #Parkinsons #microbiome #GutBrainAxis #DDDD $LBS

https://t.co/fpfQukClkz

[4D pharma @4dpharmaplc]

MRx0005 and MRx0029 #Parkinsons IND approvals covered in today's BioPharma Reporter, as well as a re-cap of our #asthma data released in January for MRx-4DP0004

https://t.co/JjajPLtsAo

#DDDD $LBPS

[4D pharma @4dpharmaplc]

Today we announced that the US FDA has cleared IND applications for @4dpharmaplc’s #LiveBiotherapeutics MRx0005 and MRx0029 for the treatment of #Parkinsons, and Phase I trial in patients is expected to commence mid-2022

https://t.co/uXrPyXwVww

#GutBrainAxis #microbiome

[4D pharma @4dpharmaplc]

Today marks @uicc World Cancer Day - raising awareness of one of the leading causes of death worldwide.

4D Pharma are proud to contribute to helping patients through developing novel and safe LBPs. Learn more at https://t.co/r8GjtHrrd7
#WorldCancerDay #Cancer #DDDD $DDDD $LBPS

[4D pharma @4dpharmaplc]

@AimHardy Link is available now @AimHardy https://t.co/PSXSgvQduC

[4D pharma @4dpharmaplc]

Today @4dpharmaplc will discuss how we are developing #LiveBiotherapeutics targeting the #GutBrainAxis to treat #Parkinsons at an event hosted by North of Scotland Parkinson’s Research Interest Group (NoSPRIG) and Dundee Research Interest Group (DRIG)
https://t.co/2oYOS0giXR

[4D pharma @4dpharmaplc]

#ICYMI Replays of two recent events available via the Events page of our website at https://t.co/PSXSgvQduC

- 27 Jan, MRx-4DP0004 #Asthma Phase 1/2 Part A Results with Prof. Chris Brightling
- 31 Jan, #LiveBiotherapeutics for #Parkinsons, hosted by NoSPRIG, DRIG, @ParkinsonsUK

[4D pharma @4dpharmaplc]

We caught up with @GENbio to discuss how @4dpharmaplc approaches the development of 'Bacteria as Therapeutics', from the MicroRx platform and #LiveBiotherapeutic discovery, to in-house manufacturing and clinical development

https://t.co/UKhBi03hy8

#DDDD $LBPS #microbiome